Will taking eltrombopag/eltrombopag reduce platelets?

As a thrombopoietin receptor agonist, Eltrombopag's core function is to activate the TPO-R receptor on the surface of hematopoietic stem cells in the bone marrow to promote the proliferation and maturation of platelet precursor cells, thereby increasing the platelet count in peripheral blood. In theory, the goal of this drug is to "raise platelets," so it sounds completely unrelated to "lowering platelets." However, in actual clinical use, there are indeed cases where individual patients' platelets do not rise but fall after taking the medicine, causing questions among patients and their families.

This phenomenon does not mean that eltrombopag directly causes thrombocytopenia, but may be caused by multiple indirect mechanisms or individual factors. First of all, some patients have abnormal drug metabolism or malabsorption. Especially when taking drugs on an empty stomach or ingesting foods high in calcium (such as dairy products), the bioavailability of the drug may be significantly reduced, resulting in insufficient blood drug concentration in the body and inability to stimulate platelet production. Such"ineffective reactions" may be misinterpreted as "drug-induced platelet decline."

Secondly, Eltrombopag may also trigger complex reactions in immune system regulation. Some patients experience transient platelet fluctuations in the early stages of treatment, manifested as "first falling and then rising" or "pseudo-dropping." This is not a side effect of the drug itself, but a temporary feedback of the individual immune environment to external intervention. In addition, the progression of some underlying diseases or combined infections can also interfere with hematopoietic function, thereby masking the original effect of the drug.

What needs to be more vigilant is that once there is excessive stimulation during drug use, platelets rise for a time, and if the drug is suddenly stopped or the dose is improperly adjusted, it may also induce "rebound thrombocytopenia". This mechanism is similar to the adrenal suppression caused by sudden discontinuation of corticosteroids after long-term use, and is a common feedback regulation disorder in drug intervention.

Reference materials:https://go.drugbank.com/drugs/DB06210